Introduction {#tca13121-sec-0005}
============

Lobectomy, along with systematic lymph node dissection (SLND), including mediastinal and hilar lymphadenectomy, remains the primary and preferred approach for the treatment of early stage non‐small cell lung cancer (NSCLC).[1](#tca13121-bib-0001){ref-type="ref"} However, not all NSCLC patients have mediastinal lymph node metastasis and whether SLND is necessary for all early‐stage NSCLC patients is controversial. With advances in early‐stage lung cancer detection and more comprehensive study of lymphatic drainage and the metastasis pathway, the lymph node spread pattern in NSCLC has been investigated in detail and it has been determined that nodal metastasis follows a predictable lobe‐specific manner.[2](#tca13121-bib-0002){ref-type="ref"}, [3](#tca13121-bib-0003){ref-type="ref"}, [4](#tca13121-bib-0004){ref-type="ref"}, [5](#tca13121-bib-0005){ref-type="ref"} Based on this, several scholars have advocated that nodal dissection in the lobe‐specific lymphatic drainage region (LSDR), so called "selective lymphadenectomy," may be sufficient, especially for early‐stage NSCLC.[6](#tca13121-bib-0006){ref-type="ref"}, [7](#tca13121-bib-0007){ref-type="ref"}, [8](#tca13121-bib-0008){ref-type="ref"} Ishiguro *et al*. suggested that it is more reasonable to perform selective LND, especially in patients with no apparent lymph node metastasis, poor pulmonary reserve, or elderly patients.[9](#tca13121-bib-0009){ref-type="ref"}

Nevertheless, selective lymphadenectomy has not been broadly accepted, partly because it is unknown whether lymph node involvement could occur in non‐LSDRs in a lobe‐specific pattern, and the correlation of nodal spread in LSDRs and non‐LSDRs and the predictors for nodal metastasis in non‐LSDRs are not very clear.

Therefore, the purpose of this study was to investigate the relation of nodal spread between LSDRs and non‐LSDRs and variables affecting lymph node metastasis in non‐LSDRs to provide reliable evidence to evaluate the rationality of lobe‐specific nodal dissection for clinical stage IA NSCLC patients.

Methods {#tca13121-sec-0006}
=======

Study design and patient selection {#tca13121-sec-0007}
----------------------------------

We selected 760 patients with primary clinical stage IA NSCLC who underwent lobectomy with systematic hilar and mediastinal LND between June 2014 and June 2018. One hundred eighty‐three patients without positron emission tomography‐computed tomography (PET‐CT) results with tumor diameters \> 1 cm, 34 patients with multiple lung lesions, 211 patients who did not meet the established study criteria for SLND, and 16 patients with a history of other non‐pulmonary malignancies were excluded. A total of 316 patients were enrolled in the study (Fig [1](#tca13121-fig-0001){ref-type="fig"}). Clinicopathological information was retrospectively collected. Clinical and pathological staging was determined based on the 8th edition American Joint Council on Cancer Tumor Node Metastasis Staging system. This study was approved by the Institutional Review Board and conducted according to the guidelines approved by the ethics committee.

![Flowchart of eligible patients enrolled in this study. NSCLC, non‐small cell lung cancer; PET‐CT, positron emission tomography‐computed tomography; pGGO, pure ground‐glass opacity.](TCA-10-1597-g001){#tca13121-fig-0001}

Preoperative evaluation {#tca13121-sec-0008}
-----------------------

Whole body PET‐CT or contrast‐enhanced chest CT scans were performed preoperatively. Other routine preoperative examinations of lung cancer patients included chest radiography, abdominal ultrasonography, magnetic resonance imaging of the brain, bone scan, bronchoscopy, and cardiopulmonary function tests. All enrolled patients underwent curative lobectomy and lymphadenectomy via thoracotomy or video‐assisted thoracic surgery (VATS).

Lobe‐specific lymphatic drainage region (LSDR) {#tca13121-sec-0009}
----------------------------------------------

The lobe‐specific pattern of nodal metastasis is widely recognized. We classified the sites of hilar and mediastinal lymph nodes into LSDR and non‐LSDR according to each lobe based on previous studies and International Association for the Study of Lung Cancer staging.[2](#tca13121-bib-0002){ref-type="ref"}, [9](#tca13121-bib-0009){ref-type="ref"}, [10](#tca13121-bib-0010){ref-type="ref"}, [11](#tca13121-bib-0011){ref-type="ref"} The LSDR and non‐LSDR of different tumor locations are shown in Table [1](#tca13121-tbl-0001){ref-type="table"}. LSDRs were defined as: stations 2R, 4R, and 10 for right upper lobe tumors; stations 7 and 10 for the right middle lobe; stations 2L, 4L, 5, 6, and 10 for left upper lobe tumors; and stations 7, 8, 9, and 10 for lower lobe tumors on both sides. Non‐LSDRs were defined as: stations 7, 8, and 9 for both side upper lobes; stations 2R and 4R for the right middle and lower lobes; and stations 2L, 4L, 5, and 6 for the left lower lobe.

###### 

LSDRs and non‐LSDRs of different tumor locations

  Location       LSDRs              Non‐LSDRs
  -------------- ------------------ --------------
  Right upper    2R, 4R, 10         7, 8, 9
  Right middle   7, 10              2R, 4R
  Right lower    7, 8, 9, 10        2R, 4R
  Left upper     2L, 4L, 5, 6, 10   7, 8, 9
  Left lower     7, 8, 9, 10        2L, 4L, 5, 6

LSDRs, lobe‐specific lymphatic drainage regions.

Systematic lymph node dissection {#tca13121-sec-0010}
--------------------------------

SLND combined with lobectomy was performed for all patients as the standard surgical procedure and curative surgery via thoracotomy or VATS. The en block removal of all tissue including the lymph nodes and surrounding fatty tissue within anatomic landmarks was performed in SLND. Patients who underwent nodal sampling were excluded. In this study, the inclusion criteria for SLND were defined as a pathological examination of a minimum of six lymph nodes, from the hilar and at least three mediastinal stations, in which a subcarinal station must be included. For right‐side tumors, the en block fatty tissues, including stations 2R, 3, 4R, 7, 8, 9, and 10R (hilar), were removed, as well as stations 2L, 4L, 5, 6, 7, 8, 9, and 10L (hilar) on the left side. Moreover, all of the patients in this study had at least one lymph node or one mediastinal station from the non‐LSDR.

Statistical analysis {#tca13121-sec-0011}
--------------------

Continuous variables were summarized using mean ± standard deviation. Student\'s *t*, chi‐square, or Fisher\'s exact tests were used to analyze differences in clinical characteristics and frequencies of lymph node metastasis among the different groups. The Fisher\'s exact test was used to test univariate associations between pN status in non‐LSDRs and clinicopathological factors, and multivariable analysis was performed using logistic regression analysis. All data analyses were performed using SPSS version 20.0, and a *P* value of \< 0.05 was considered statistically significant.

Results {#tca13121-sec-0012}
=======

Patient characteristics {#tca13121-sec-0013}
-----------------------

The patient\'s demographic characteristics and clinicopathological information are presented in Table [2](#tca13121-tbl-0002){ref-type="table"}. The median age was 59 years (range: 31--79), and 55.1% of the patients were male. Most patients were non‐smokers (*n* = 208, 65.8%) and asymptomatic (*n* = 224, 70.9%). The median tumor size was 2.0 cm (range: 0.6--3.0). In terms of consistency on appearance, 220 patients (69.6%) had solid tumors, 55 patients (17.4%) had part‐solid tumors, and 41 patients (13.0%) had pure ground‐glass opacity (pGGO) tumors. A GGO ratio of \> 25% was found in 72 patients (22.8%). One hundred and seventy‐seven patients (56.0%) underwent VATS, while thoracotomy was performed on 139 patients (44.0%). Most tumors were located at the right upper (36.4%) and left upper (23.4%) lobes. Peripherally located tumors were found in 284 (89.9%) patients by means of pathology, and pathologic examination of the resected specimen confirmed adenocarcinoma in 285 patients (90.2%); squamous cell carcinoma in 21 patients (6.6%); and other types in 10 patients, including 4 carcinoid, 2 large cell carcinoma, 3 adenosquamous carcinoma, and 1 sarcomatoid carcinoma. Of the 309 patients whose tumor differentiation was evaluated, well‐differentiated tumors were observed in 73 patients (23.6%), while moderately and poorly differentiated tumors were observed in 173 (56.0%) and 63 (20.4%) patients, respectively. There were 255 node‐negative patients (80.7%) and lymph node metastases were found in 61 patients (19.3%): 31 had pN1 disease and 30 had pN2 disease. One hundred thirteen (35.8%) patients were at stage IA, 137 (43.4%) patients with invasion of the visceral pleura were at stage IB, 32 (10.1%) patients were at stage II, and 33 patients (10.4%) were at stages IIIA and IIIB.

###### 

Baseline characteristics of 316 patients

  Variables                                                                        Total
  ------------------------------------------------------------------------ ---------------------
  Age, years, median (range)                                                    59 (31--79)
  Gender, *n* (%)                                                          
  Male                                                                          174 (55.1)
  Female                                                                        142 (44.9)
  Smoking status, *n* (%)                                                  
  Never                                                                         208 (65.8)
  Former and current                                                            108 (34.2)
  Symptom status, *n* (%)                                                  
  Asymptomatic                                                                  224 (70.9)
  Symptomatic                                                                    92 (29.1)
  Preoperative CEA level, *n* (%)[†](#tca13121-note-0002){ref-type="fn"}   
  ≤ 5 ng/mL                                                                      230 (5.5)
  \> 5 ng/mL                                                                     39 (14.5)
  Tumor SUVmax[‡](#tca13121-note-0003){ref-type="fn"}                      
  ≤ 2.5                                                                          83 (33.1)
  \> 2.5                                                                        168 (66.9)
  Tumor size, cm, median (range)                                              2.0 (0.6--3.0)
  Consistency, *n* (%)                                                     
  Solid                                                                         220 (69.6)
  Part solid                                                                     55 (17.4)
  Pure GGO                                                                       41(13.0)
  GGO ratio, *n* (%)                                                       
  ≤ 25%                                                                         244 (77.2)
  \> 25%                                                                         72 (22.8)
  Approach, *n* (%)                                                        
  VATS                                                                          177 (56.0)
  Thoracotomy                                                                   139 (44.0)
  Lobe of tumor, *n* (%)                                                   
  Right upper                                                                   115 (36.4)
  Right middle                                                                   22 (7.0)
  Right lower                                                                    62 (19.6)
  Left upper                                                                     74 (23.4)
  Left lower                                                                     43 (13.6)
  Location, *n* (%)                                                        
  Central                                                                        32 (10.1)
  Peripheral                                                                    284 (89.9)
  Cell type, *n* (%)                                                       
  ADC                                                                           285 (90.2)
  Non‐ADC                                                                        31 (9.8)
  Differentiation, *n* (%)[§](#tca13121-note-0004){ref-type="fn"}          
  Well Moderately                                                           73 (23.6)173 (56.0)
  Poorly                                                                         63 (20.4)
  pN status, *n* (%)                                                       
  pN0                                                                           255 (80.7)
  pN1                                                                            31 (9.8)
  pN2                                                                            30 (9.5)
  pTNM stage, *n* (%)                                                      
  0                                                                               1 (0.3)
  IA                                                                            113 (35.8)
  IB                                                                            137 (43.4)
  IIA                                                                            29 (9.2)
  IIB                                                                             3 (0.9)
  IIIA                                                                           31 (9.8)
  IIIB                                                                            2 (0.6)

Forty‐seven patients without preoperative CEA value.

Sixty‐five patients without maximum standardized uptake value (SUVmax).

Seven patients could not be evaluated.

ADC, adenocarcinoma; GGO, ground‐glass opacity; pTNM, pathological tumor node metastasis; VATS, video‐assisted thoracic surgery.

Incidence and factors of nodal involvement in non‐LSDRs {#tca13121-sec-0014}
-------------------------------------------------------

Twelve patients (3.8%) had lymph node metastasis in non‐LSDRs. In 35 patients with positive LSDR lymph nodes, the non‐LSDR lymph node metastasis rate was 31.4% (11/35). Only one (0.4%) out of 281 patients with negative LSDR lymph nodes had non‐LSDR lymph node involvement. Table [3](#tca13121-tbl-0003){ref-type="table"} shows the results of univariate analysis of clinicopathological factors associated with nodal spread in non‐LSDRs. Solid consistency (*P* = 0.021), worse differentiation (*P* = 0.034), and positive status in LSDRs (*P* \< 0.001) showed significant associations with lymph node metastasis in non‐LSDRs. There was no significant difference among patients by age, gender, smoking or symptom status, preoperative CEA level, total tumor size, approach, location, pT stage (T1 vs. T2), or cell type. In multivariate analysis, the variable identified as the independent predictor for lymph node metastasis in non‐LSDRs was pN status in LSDRs (hazard ratio \[HR\] 137.5; 95% confidence interval \[CI\] 17.0‐1114.6; *P* \< 0.001) (Table [4](#tca13121-tbl-0004){ref-type="table"}). The positive nodal stations in non‐LSDRs for each lobe in 12 patients are summarized in Table [5](#tca13121-tbl-0005){ref-type="table"}. All of the positive lymph nodes in non‐LSDRs for lung cancers in upper lobes were from subcarinal stations.

###### 

Clinicopathological factors associated with pN status in non‐LSDRs

  Variables                                                        *n*   pN(+) in non‐LSDRs *n* (%)   pN(−) in non‐LSDRs *n* (%)     *P*
  --------------------------------------------------------------- ----- ---------------------------- ---------------------------- ----------
  Age (years)                                                                   60.67 ± 7.83                 58.58 ± 8.93           0.926
  Gender                                                                                                                            0.665
  Male                                                             151            5 (3.3)                     146 (96.7)          
  Female                                                           165            7 (4.2)                     158 (95.8)          
  Smoking status                                                                                                                    1.000
  Never                                                            208            8 (3.8)                     200 (96.2)          
  Former and current                                               108            4 (3.7)                     104 (96.3)          
  Symptom status                                                                                                                    0.196
  Asymptomatic                                                     224            11 (4.9)                    213 (95.1)          
  Symptomatic                                                      92             1 (1.1)                     91 (98.9)           
  Preoperative CEA level[†](#tca13121-note-0006){ref-type="fn"}                                                                     0.140
  \> 5 ng/mL                                                       39             4 (10.3)                    35 (89.7)           
  ≤ 5 ng/mL                                                        230            8 (3.5)                     222 (96.5)          
  Tumor SUVmax[‡](#tca13121-note-0007){ref-type="fn"}                                                                               1.000
  \> 2.5                                                           168            8 (4.8)                     160 (95.2)          
  ≤ 2.5                                                            83             4 (4.8)                     79 (95.2)           
  Total size                                                                                                                        0.365
  \> 2 cm                                                          96             7 (7.2)                     89 (92.7)           
  ≤ 2 cm                                                           179            5 (2.8)                     174 (97.2)          
  Consistency                                                                                                                       0.021
  Solid                                                            220            12 (5.5)                    208 (94.5)          
  Part solid + Pure GGO                                            96             0 (0.0)                     96 (100.0)          
  GGO ratio                                                                                                                         0.041
  ≤ 25%                                                            244            12 (4.9)                    221 (95.1)          
  \> 25%                                                           72             0 (0.0)                     83 (100.0)          
  Approach                                                                                                                          0.869
  VATS                                                             177            7 (4.0)                     170 (96.0)          
  Thoracotomy                                                      139            5 (3.6)                     134 (96.4)          
  Location                                                                                                                          0.619
  Central                                                          32             0 (0.0)                     32 (100.0)          
  Peripheral                                                       284            12 (4.2)                    272 (95.8)          
  pT stage[§](#tca13121-note-0008){ref-type="fn"}                                                                                   0.308
  T1                                                               135            2 (1.5)                     133 (98.5)          
  T2                                                               172            7 (4.1)                     165 (95.9)          
  Cell type                                                                                                                         1.000
  ADC                                                              285            11 (3.9)                    274 (96.1)          
  Non‐ADC                                                          31             1 (3.2)                     30 (96.8)           
  Differentiation[¶](#tca13121-note-0009){ref-type="fn"}                                                                            0.034
  Well                                                             73             0 (0.0)                     73 (100.0)          
  Moderately                                                       173            7 (4.0)                     166 (96.0)          
  Poorly                                                           63             5 (7.9)                     58 (92.1)           
  Station 11--13                                                                                                                    0.070
  N(+)                                                             44             4 (9.1)                     40 (90.9)           
  N(−)                                                             272            8 (2.9)                     264 (97.1)          
  pN in LSDRs                                                                                                                      \< 0.001
  N(+)                                                             35            11 (31.4)                    24 (68.6)           
  N(−)                                                             281            1 (0.4)                     280 (99.6)          

Forty‐seven patients without preoperative CEA value.

Sixty five patients without maximum standardized uptake value (SUVmax).

Nine patients with stage Tis.

Seven patients could not be evaluated.

ADC, adenocarcinoma; GGO, ground glass opacity; LSDRs, lobe‐specific lymphatic drainage regions; VATS, video‐assisted thoracic surgery.

###### 

Multivariate analysis of lymph node metastasis in non‐LSDRs

  Variables          Hazard ratio   95% confidence interval     *P*
  ----------------- -------------- ------------------------- ----------
  Consistency            0.96             0.62--1.53           0.787
  GGO ratio              1.19             0.75--1.87           0.569
  Differentiation        1.06             0.67--1.83           0.858
  pN in LSDRs           137.5            17.0--1114.6         \< 0.001

GGO, ground glass opacity; LSDRs, lobe‐specific lymphatic drainage regions.

###### 

Positive nodal stations in non‐LSDRs for each lobe in 12 patients

  Location           *n*      Non‐LSDRs                 Prognosis (postoperative)
  -------------- ----------- ----------- --------------------------------------------------------
  Right upper     Patient 1       7                     No recurrence (16 months)
                  Patient 2       7                     No recurrence (33 months)
                  Patient 3       7                     Local relapse (20 months)
  Right middle    Patient 1    2R, 4R                  Lung metastasis (24 months)
  Right lower     Patient 1      2R                          Died (13 months)
  Left upper      Patient 1       7                     No recurrence (46 months)
                  Patient 2       7                     Bone metastasis (5 months)
                  Patient 3       7                    Lung metastasis (30 months)
                  Patient 4       7       Left supraclavicular lymph node metastasis (27 months)
  Left lower      Patient 1      4L                     No recurrence (36 months)
                  Patient 2      4L                    Brain metastasis (10 months)
                  Patient 3       5                   Pleural metastasis (15 months)

LSDRs, lobe‐specific lymphatic drainage regions.

Discussion {#tca13121-sec-0015}
==========

It has been widely recognized that adequate lymph node assessment plays a vital role in the accurate staging and prognostic evaluation of NSCLC patients,[12](#tca13121-bib-0012){ref-type="ref"} for which SLND has been universally recommended and accepted.[13](#tca13121-bib-0013){ref-type="ref"} However, because of an increase in the detection of early‐stage lung cancer, some scholars have advocated that this classic approach might not be necessary for all early‐stage lung cancer patients. In our study, univariate analysis identified solid consistency, worse differentiation, and lymph node metastasis in LSDRs as unfavorable predictive variables for pN status in non‐LSDRs. Moreover, multivariate analysis revealed that pN status in LSDRs was an independent predictor for lymph node metastasis in non‐LSDRs (*P* \< 0.001). In other words, non‐LSDR lymph node metastasis mainly depends on LSDR lymph node involvement. Thus, it could be a useful index for planning limited surgical resection and benefit surgeons in the management of lymphadenectomy for stage IA NSCLC patients, especially when selective lymphadenectomy is suggested as an acceptable mode of dissection, at least for selected populations.

We classified the sites of hilar and mediastinal lymph nodes into LSDRs and non‐LSDRs. Detailed descriptions of the drainage regions of the different lobes are presented in Table [1](#tca13121-tbl-0001){ref-type="table"}. At present, the lobe‐specific pattern of nodal metastasis is widely recognized and there is growing evidence that the extent of LND could be tailored for patients with early‐stage NSCLC. Upper lobe cancers tend to metastasize to the superior mediastinal lymph node. If the hilar or superior mediastinal lymph node is not involved, positive subcarinal lymph node metastasis is rarely found. In addition, the probability of skipping metastasis from lower lobe lesions to the upper mediastinum is very low.[2](#tca13121-bib-0002){ref-type="ref"}, [3](#tca13121-bib-0003){ref-type="ref"}, [4](#tca13121-bib-0004){ref-type="ref"}, [5](#tca13121-bib-0005){ref-type="ref"}, [14](#tca13121-bib-0014){ref-type="ref"} Based on these results, researchers have argued that selective mediastinal dissection is as effective as SLND, and does not negatively impact the survival of patients.[9](#tca13121-bib-0009){ref-type="ref"}, [15](#tca13121-bib-0015){ref-type="ref"} However, many previous studies did not report the incidence of nodal involvement in non‐LSDRs when lymph nodes are positive in LSDRs. We found that for 35 patients with positive lymph nodes in LSDRs, the nodal metastasis rate in non‐LSDRs was 31.4%, while only one (0.4%) among 281 patients with negative LSDR lymph nodes had non‐LSDR lymph node involvement. The rarity of non‐LSDR lymph node involvement in patients with negative LSDRs may highlight the feasibility and necessity of selective lymphadenectomy for early‐stage NSCLC patients. But for those with positive LSDR nodes, SLND might well be preferable to a selective mode. Thus, it would provide thoracic surgeons with more reliable information on lymph node metastasis and allow them to be more cautious in performing complete or selective LND.

Intraoperative lymph node assessment for the rapid examination of frozen sections to select the appropriate type of dissection has been described or recommended by researchers in European Society of Thoracic Surgeons (ESTS) guidelines and previous literature.[15](#tca13121-bib-0015){ref-type="ref"}, [16](#tca13121-bib-0016){ref-type="ref"}, [17](#tca13121-bib-0017){ref-type="ref"}, [18](#tca13121-bib-0018){ref-type="ref"} Therefore fully examining all dissected lymph nodes in LSDRs would be feasible, although it may be difficult or complicated. We do not recommend that nodal examination in the time of an operation should be taken into account as a routine practice, but we do believe it will contribute to the adequate assessment of non‐LSDR lymph node metastasis.

Univariate analysis indicated that patients with solid tumors (*P* = 0.021) and a GGO ratio \< 25% (*P* = 0.041) were more prone to lymph node involvement in non‐LSDRs, although the power was lost in multivariate analysis. The solid component represents the portion of invasive growth, and lung adenocarcinoma with a wider GGO area always has a better prognosis.[19](#tca13121-bib-0019){ref-type="ref"}, [20](#tca13121-bib-0020){ref-type="ref"} Therefore, preoperative examination of radiological appearance would be significant to determine an appropriate LND method and solid consistency, or the GGO ratio could be a useful index of prediction for pN status in non‐LSDRs.

Of the 309 patients with available tumor differentiation information, positive lymph node involvement in non‐LSDRs was present in patients with moderately and poorly differentiated tumors, significantly higher than the patients with well‐differentiated tumors. Information on the histological degree of differentiation information can be obtained not only from postoperative surgical specimens, but also from preoperative biopsy specimens or intraoperative frozen sections. Therefore, identification of the degree of differentiation in preoperative biopsy specimens or intraoperative frozen sections might alert thoracic surgeons to the possibility of lymph node metastasis in non‐LSDRs, and would be helpful to narrow down eligible candidates for minimally invasive LND.

Previous studies reported that the lymphatic route of sentinel node migration to mediastinal stations was also lobe‐specific and the station of the sentinel node at the mediastinum mainly located in LSDR for each lobe.[21](#tca13121-bib-0021){ref-type="ref"}, [22](#tca13121-bib-0022){ref-type="ref"} The sentinel node is defined as the first lymph node that the lymphatic flux flows into from the primary tumor and should be the first site metastasis occurs in. The utility and feasibility of sentinel node mapping for NSCLC has been demonstrated and improved using different techniques.[23](#tca13121-bib-0023){ref-type="ref"}, [24](#tca13121-bib-0024){ref-type="ref"} Thus, the status of the sentinel node for each lobe may be important to indicate the likelihood of nodal involvement in LSDRs for NSCLC patients, which may provide more information for determining LND approach. However, further investigation is necessary.

There were some limitations to our study. First, it was inevitable that an inherent selection bias was present, because of the design nature of a retrospective study. Second, the mode of mediastinal lymph node metastasis based on a lobe‐specific manner is a very complicated issue; therefore the study of lobe‐specific nodal metastasis requires further investigation, although it has a certain rationality. The clinical JCOG1413 trial commenced in January 2017 and will be the first phase III trial to confirm the benefit of lobe‐specific nodal dissection for clinical stage I--II NSCLC.[25](#tca13121-bib-0025){ref-type="ref"} We hope that the conclusions of this ongoing randomized trial will contribute to a clarification of whether selective lymphadenectomy is equal to SLND as a potential nodal dissection approach for stage IA NSCLC.

In conclusion, in this study, 19.3% of clinical stage IA NSCLC patients showed unexpected lymph node metastasis. Solid consistency, degree of differentiation, and pN status in LSDRs were predictive factors for lymph node metastasis in non‐LSDRs, while multivariate analysis showed that lymph node metastasis in LSDRs was the only independent predictor. Our results provide thoracic surgeons with more reliable information to assess non‐lobe‐specific lymph node metastasis in clinical stage IA NSCLC patients and will contribute to clinical decision‐making for a reasonable approach to LND.
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